This has been a tough time for small-cap investors as risk appetite waned, but some sectors have taken an added blow due to a dismal update by a major player in that space.

Biotech stocks are one example after sentiment towards the sector was hit by news that Pharmaxis was unlikely to get final approval from European regulators next month for its drug Bronchitol.